Trasylol Linked to Over 20,000 Deaths

-houston.injuryboard.com

02/26/2008 - A recent study found that patients that received Bayer's Trasylol during heart surgery were significantly more likely to die within the next decade. Another study of 78,000 patients, originally withheld by Bayer, found a 78 percent increased risk of death within a week following the surgery. In November Bayer suspended sales of Trasylol after a Canadian trial linked the drug to higher death rates. The FDA approved Trasylol in 1993 to help reduce bleeding during open-heart surgery and by 2005 had become "part of the fabric of cardiac surgery," but a 2006 study linked the drug to higher rates of heart attack, stroke, kidney failure and death sparking widespread concern.

Bayer challenged the findings from the most recent studies claiming that the data analysis was flawed. Two panels of experts have advised the FDA to keep the drug on the market citing inconclusive evidence. Trasylol is still available through a restricted access program.

It is not clear when a decision will be made about the future of Trasylol, but the FDA is in the process of reviewing the data.

Ennis & Ennis, P.A. is representing individuals that have been harmed as a result of Trasylol side effects. If you or a loved one have suffered as a result of Trasylol side effects such as kidney failure, heart attack, or stroke you may be entitled to compensation. For more information about a Trasylol lawsuit, a possible Trasylol recall, or for questions regarding Trasylol class action lawsuits click here for a free, confidential case evaluation.